Thrivent Financial for Lutherans’s GSK GSK Stock Holding History

Thrivent Financial for Lutherans’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,118	Closed	-$742K	–	2603
2025 Q4	$742K	Buy	15,118 +8,600	+132%	+$401K	﹤0.01%	2099
2025 Q3	$281K	Sell	6,518 -8,099	-55%	-$316K	﹤0.01%	2250
2025 Q2	$562K	Sell	14,617 -340	-2%	-$13K	﹤0.01%	2092
2025 Q1	$544K	Sell	14,957 -34,907	-70%	-$1.28M	﹤0.01%	2037
2024 Q4	$1.73M	Sell	49,864 -3,484	-7%	-$125K	﹤0.01%	1542
2024 Q3	$2.18M	Buy	53,348 +1,737	+3%	+$71.1K	﹤0.01%	1379
2024 Q2	$1.99M	Sell	51,611 -1,082	-2%	-$45.5K	﹤0.01%	1381
2024 Q1	$2.26M	Buy	52,693 +3,831	+8%	+$158K	﹤0.01%	1321
2023 Q4	$1.81M	Buy	48,862 +16,799	+52%	+$603K	﹤0.01%	1446
2023 Q3	$1.16M	Sell	32,063 -201	-0.6%	-$7.13K	﹤0.01%	1646
2023 Q2	$1.15M	Buy	32,264 +492	+2%	+$17.6K	﹤0.01%	1715
2023 Q1	$1.13M	Buy	31,772 +145	+0.5%	+$5.07K	﹤0.01%	1708
2022 Q4	$1.11M	Buy	31,627 +1,012	+3%	+$33.7K	﹤0.01%	1658
2022 Q3	$901K	Sell	30,615 -1,277,531	-98%	-$48.4M	﹤0.01%	1748
2022 Q2	$71.2M	Buy	1,308,146 +527,644	+68%	+$29.1M	0.19%	141
2022 Q1	$42.5M	Buy	780,502 +38,856	+5%	+$2.11M	0.08%	277
2021 Q4	$40.9M	Buy	741,646 +15,216	+2%	+$792K	0.08%	287
2021 Q3	$34.7M	Buy	726,430 +3,144	+0.4%	+$158K	0.07%	310
2021 Q2	$36M	Buy	723,286 +5,762	+0.8%	+$277K	0.07%	307
2021 Q1	$32M	Buy	717,524 +16,924	+2%	+$768K	0.07%	326
2020 Q4	$32.2M	Sell	700,600 -26,848	-4%	-$1.23M	0.07%	326
2020 Q3	$34.2M	Sell	727,448 -12,656	-2%	-$634K	0.09%	260
2020 Q2	$37.7M	Buy	740,104 +732,841	+10,090%	+$37.6M	0.11%	223
2020 Q1	$344K	Buy	+7,263	New	+$387K	﹤0.01%	1915
2019 Q4	–	Sell	-44,030	Closed	-$2.35M	–	2233
2019 Q3	$2.35M	Sell	44,030 -2,608	-6%	-$134K	0.01%	919
2019 Q2	$2.33M	Buy	46,638 +14,992	+47%	+$752K	0.01%	916
2019 Q1	$1.65M	Sell	31,646 -11,968	-27%	-$598K	0.01%	1066
2018 Q4	$2.08M	Sell	43,614 -1,011,108	-96%	-$49.8M	0.01%	822
2018 Q3	$53M	Buy	1,054,722 +7,048	+0.7%	+$358K	0.17%	159
2018 Q2	$52.8M	Sell	1,047,674 -46,278	-4%	-$2.33M	0.17%	136
2018 Q1	$53.4M	Sell	1,093,952 -73,300	-6%	-$3.41M	0.18%	127
2017 Q4	$51.8M	Sell	1,167,252 -38,419	-3%	-$1.77M	0.17%	129
2017 Q3	$61.2M	Buy	1,205,671 +11,590	+1%	+$588K	0.22%	116
2017 Q2	$64.4M	Buy	1,194,081 +95,628	+9%	+$5.1M	0.27%	97
2017 Q1	$57.9M	Buy	1,098,453 +1,097,192	+87,010%	+$55.7M	0.25%	101
2016 Q4	$62K	Sell	1,261 -800	-39%	-$39.5K	﹤0.01%	1875
2016 Q3	$111K	Sell	2,061 -60	-3%	-$3.29K	﹤0.01%	1875
2016 Q2	$115K	Buy	2,121 +77	+4%	+$4.06K	﹤0.01%	1860
2016 Q1	$106K	Hold	2,044	–	–	﹤0.01%	1833
2015 Q4	$103K	Buy	+2,044	New	+$104K	﹤0.01%	1828
2015 Q3	–	Sell	-2,044	Closed	-$106K	–	1826
2015 Q2	$106K	Hold	2,044	–	–	﹤0.01%	1679
2015 Q1	$121K	Sell	2,044 -40	-2%	-$2.29K	﹤0.01%	1656
2014 Q4	$113K	Buy	2,084 +800	+62%	+$44.8K	﹤0.01%	1671
2014 Q3	$73K	Buy	+1,284	New	+$78.7K	﹤0.01%	1710
2013 Q3	–	Sell	-4,240	Closed	-$265	–	1560
2013 Q2	$265	Buy	+4,240	New	+$269K	﹤0.01%	1277

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Thrivent Financial for Lutherans's GSK Position: Q1 2026 in Review

Thrivent Financial for Lutherans sold out of GSK (GSK) in Q1 2026, closing a stake of 15,118 shares — an estimated $742K sold.

Thrivent Financial for Lutherans first reported a position in GSK in Q2 2013 and held it in 45 quarters. The position peaked at $71.2M in Q2 2022. 1,035 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Thrivent Financial for Lutherans reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Thrivent Financial for Lutherans sold 15,118 GSK shares in Q1 2026, an estimated $742K.
Thrivent Financial for Lutherans first reported a position in GSK in Q2 2013 and held it in 45 quarters.
Thrivent Financial for Lutherans's GSK position peaked at $71.2M in Q2 2022.
1,035 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.